Clinical Trials

1 trials
RecentStart dateEnrollment
Chromosome 5q Deletion Syndrome × Enzyme-Linked Immunosorbent Assay × Plasma cell × Clear all
NCT01273766 2018-09-07

Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies

Wake Forest University Health Sciences

Phase 2 Completed
16 enrolled 10 charts
Classical hematologyDermatologicLymphoidMyeloidOther hematologic neoplasmPlasma cell

Chromosome 5q Deletion Syndrome, Congenital Abnormalities, Anemia, Refractory, Burkitt Lymphoma, Histiocytosis, Langerhans-Cell, Hodgkin Disease, Immunoblastic Lymphadenopathy, Leukemia, Mast-Cell, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Mycosis Fungoides, Myeloproliferative Disorders, Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell, Primary Myelofibrosis, Intraocular Lymphoma